Patents by Inventor Catherine R. Kostlan

Catherine R. Kostlan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130178446
    Abstract: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.
    Type: Application
    Filed: March 4, 2013
    Publication date: July 11, 2013
    Applicant: Medicis Pharmaceutical Corporation
    Inventors: Catherine R. Kostlan, Raj Neil Raheja, Meera Tugnait, Kimberly Wade
  • Patent number: 8409595
    Abstract: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: April 2, 2013
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Catherine R. Kostlan, Raj Neil Raheja, Meera Tugnait, Kimberly Wade
  • Publication number: 20100113601
    Abstract: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.
    Type: Application
    Filed: September 29, 2009
    Publication date: May 6, 2010
    Applicant: Graceway Pharmaceuticals, LLC
    Inventors: Catherine R. Kostlan, Raj Neil Raheja, Meera Tugnait, Kimberly Wade
  • Patent number: 7615230
    Abstract: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.
    Type: Grant
    Filed: October 5, 2004
    Date of Patent: November 10, 2009
    Assignee: Graceway Pharmaceuticals, LLC
    Inventors: Catherine R. Kostlan, Raj Neil Raheja, Meera Tugnait, Kimberly Wade
  • Patent number: 5432181
    Abstract: The present invention is novel compounds which are 4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidine substituted 1,2,4- and 1,3,4-thiadiazoles and oxadiazoles, and 1,2,4-triazoles, and pharmaceutically acceptable additions and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and particularly rheumatoid arthritis, osteoarthritis, other inflammatory conditions, psoriasis, allergic diseases, asthma, inflammatory bowel disease, GI ulcers, cardiovascular conditions, including ischemic heart disease and atherosclerosis, and ischemia-induced cell damage, particularly brain damage caused by stroke. They can also be used topically for treating acne, sunburn, psoriasis, and eczema.
    Type: Grant
    Filed: July 12, 1994
    Date of Patent: July 11, 1995
    Assignee: Warner-Lambert Company
    Inventors: Thomas R. Belliotti, Catherine R. Kostlan, David T. Connor
  • Patent number: 5376670
    Abstract: The present invention is novel compounds which are 3,5-di-tertiary-butyl-4-hydroxyphenyl substituted 1,2,4- and 1,3,4-thiadazoles and oxadiazoles, and 1,2,4-triazoles, and pharmaceutically acceptable additions and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and the like.
    Type: Grant
    Filed: July 13, 1993
    Date of Patent: December 27, 1994
    Assignee: Warner-Lambert Company
    Inventors: David T. Connor, Daniel L. Flynn, Catherine R. Kostlan, Michael D. Mullican, Gary P. Shrum, Paul C. Unangst, Michael W. Wilson
  • Patent number: 5356898
    Abstract: The present invention is novel compounds which are 4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidine substituted 1,2,4- and 1,3,4-thiadiazoles and oxadiazoles, and 1,2,4-triazoles, and pharmaceutically acceptable additions and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and particularly rheumatoid arthritis, osteoarthritis, other inflammatory conditions, psoriasis, allergic diseases, asthma, inflammatory bowel disease, GI ulcers, cardiovascular conditions, including ischemic heart disease and atherosclerosis, and ischemia-induced cell damage, particularly brain damage caused by stroke. They can also be used topically for treating acne, sunburn, psoriasis, and eczema.
    Type: Grant
    Filed: July 1, 1993
    Date of Patent: October 18, 1994
    Assignee: Warner-Lambert Company
    Inventors: Thomas R. Belliotti, Catherine R. Kostlan, David T. Connor
  • Patent number: 5348957
    Abstract: The present invention compounds are 5-hydroxy-2-pyrimidinylmethylene derivatives and pharmaceutically acceptable addition salts, bases, and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of, for example, inflammation and GI ulcers.
    Type: Grant
    Filed: August 6, 1993
    Date of Patent: September 20, 1994
    Assignee: Warner-Lambert Company
    Inventors: Thomas R. Belliotti, David T. Connor, Catherine R. Kostlan
  • Patent number: 5340815
    Abstract: The present invention is novel compounds which are 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines and pharmaceutically acceptable acid addition or base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever and the like. Thus, the present invention is also a pharmaceutical composition or method of manufacturing a pharmaceutical composition for the use of treating the noted conditions.
    Type: Grant
    Filed: July 1, 1993
    Date of Patent: August 23, 1994
    Assignee: Warner-Lambert Company
    Inventors: David T. Connor, Catherine R. Kostlan
  • Patent number: 5338737
    Abstract: Novel heterocyclic methyl derivatives of biphenyl oxadiazoles and thiadiazoles are described, as well as methods for the preparation of said derivatives and pharmaceutical compositions of the same, which are useful as antagonists of the angiotensin II enzyme and thus useful in treating hypertension, hyperaldosteronism, congestive heart failure, and glaucoma.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: August 16, 1994
    Assignee: Warner-Lambert Company
    Inventors: David T. Connor, Catherine R. Kostlan
  • Patent number: 5312821
    Abstract: The present invention is novel compounds which are 2-heterocyclic-4,6-ditertiarybutyl-5-hydroxy-1,3-pyrimidines, where heterocyclic is selected from imidazole, thiazole, and oxazole, and pharmaceutically acceptable additional salts, bases, and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of, for example, inflammation.
    Type: Grant
    Filed: April 28, 1993
    Date of Patent: May 17, 1994
    Assignee: Warner-Lambert Company
    Inventors: David T. Connor, Catherine R. Kostlan, Paul C. Unangst
  • Patent number: 5302597
    Abstract: The present invention is novel compounds which are 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines and pharmaceutically acceptable acid addition or base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever and the like. Thus, the present invention is also a pharmaceutical composition or method of manufacturing a pharmaceutical composition for the use of treating the noted conditions.
    Type: Grant
    Filed: June 10, 1993
    Date of Patent: April 12, 1994
    Assignee: Warner-Lambert Company
    Inventors: David T. Connor, Catherine R. Kostlan
  • Patent number: 5284949
    Abstract: The present invention is novel compounds which are 2-substituted amino-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines and pharmaceutically acceptable acid addition or base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are described as having activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever and the like. Thus, the present invention is also a pharmaceutical composition or method of manufacturing a pharmaceutical composition for the use of treating the noted conditions.
    Type: Grant
    Filed: March 10, 1993
    Date of Patent: February 8, 1994
    Assignee: Warner-Lambert Company
    Inventors: Thomas R. Belliotti, David T. Connor, Catherine R. Kostlan
  • Patent number: 5270319
    Abstract: The present invention is novel compounds which are 5-hydroxy-2-pyrimidinylmethylene derivatives and pharmaceutically acceptable addition salts, bases, and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of, for example, preferably inflammation.
    Type: Grant
    Filed: July 7, 1992
    Date of Patent: December 14, 1993
    Assignee: Warner-Lambert Company
    Inventors: Thomas R. Belliotti, David T. Connor, Catherine R. Kostlan
  • Patent number: 5256680
    Abstract: The present invention is novel compounds which are 3,5-di-tertiary-butyl-4-hydroxyphenyl substituted 1,2,4- and 1,3,4-thiadazoles and oxadiazoles, and 1,2,4-triazoles, and pharmaceutically acceptable additions and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and the like.
    Type: Grant
    Filed: June 29, 1992
    Date of Patent: October 26, 1993
    Assignee: Warner-Lambert Company
    Inventors: David T. Connor, Daniel L. Flynn, Catherine R. Kostlan, Michael D. Mullican, Gary P. Shrum, Paul C. Unangst, Michael W. Wilson
  • Patent number: 5248682
    Abstract: The present invention is novel compounds which are 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines and pharmaceutically acceptable acid addition or base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever and the like. Thus, the present invention is also a pharmaceutical composition or method of manufacturing a pharmaceutical composition for the use of treating the noted conditions.
    Type: Grant
    Filed: August 3, 1992
    Date of Patent: September 28, 1993
    Assignee: Warner-Lambert Company
    Inventors: David T. Connor, Catherine R. Kostlan
  • Patent number: 5240929
    Abstract: The present invention is novel compounds which are 2-heterocyclic-4,6-ditertiarybutyl-5-hydroxy-1,3-pyrimidines, where heterocyclic is selected from imidazole, thiazole, and oxazole, and pharmaceutically acceptable additional salts, bases, and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of, for example, preferably inflammation.
    Type: Grant
    Filed: August 3, 1992
    Date of Patent: August 31, 1993
    Assignee: Warner-Lambert Company
    Inventors: David T. Connor, Catherine R. Kostlan, Paul C. Unangst
  • Patent number: 5220025
    Abstract: The present invention is novel compounds which are 2-substituted amino-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines and pharmaceutically acceptable acid addition or base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are described as having activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever and the like. Thus, the present invention is also a pharmaceutical composition or method of manufacturing a pharmaceutical composition for the use of treating the noted conditions.
    Type: Grant
    Filed: November 16, 1992
    Date of Patent: June 15, 1993
    Assignee: Warner-Lambert Company
    Inventors: Thomas R. Belliotti, David T. Connor, Catherine R. Kostlan
  • Patent number: 5215986
    Abstract: Novel 5, 6, or 7 membered oxaza heterocycles substituted at the 4-carbon by a 5-hydroxypyrimidinylmethylene group inhibitors of 5-lipoxygenase and/or cyclooxygenase and are thus useful in treating inflammatory diseases are described as well as pharmaceutical compositions, methods of manufacture of the compounds, and compositions and methods of treating the noted diseases.
    Type: Grant
    Filed: June 1, 1992
    Date of Patent: June 1, 1993
    Assignee: Warner-Lambert Company
    Inventors: David T. Connor, Catherine R. Kostlan, Gary P. Shrum, Paul C. Unangst
  • Patent number: 5212189
    Abstract: The present invention is a novel compound which is a thiadiazole or oxadiazole analog of a fenamic acid having a substituted hydroxamate side chain and pharmaceutically acceptable acid addition or base salts thereof, pharmaceutical compositions and methods of use thereof. The invention compounds are now found to have activity as inhibitors of one or both of cyclooxygenase and 5-lipoxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and the like. Thus, the present invention is also a pharmaceutical composition or method of use thereof.
    Type: Grant
    Filed: December 17, 1991
    Date of Patent: May 18, 1993
    Assignee: Warner-Lambert Company
    Inventors: Thomas R. Belliotti, David T. Connor, Catherine R. Kostlan